Saniona Logo

Saniona

Develops ion channel medicines for rare neurological diseases and epilepsy.

SANION | ST

Overview

Corporate Details

ISIN(s):
SE0005794617 (+1 more)
LEI:
549300XO4L9XNOCFCZ84
Country:
Denmark
Address:
Smedeland 26 B, 2600 GLOSTRUP
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Saniona is a clinical-stage biopharmaceutical company specializing in the discovery and development of proprietary medicines for rare diseases. A pioneer in ion channel research, the company leverages its expertise in highly specific ion channel modulation to develop treatments for neurological and psychiatric disorders, with a key focus on epilepsy. Saniona operates a robust drug discovery engine supported by a proprietary library of over 20,000 molecules, advancing a pipeline of potential new medicines through clinical trials to address high unmet medical needs.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-27 08:00
Quarterly Report
Swedish 1000.5 KB
2025-11-27 08:00
Quarterly Report
English 887.7 KB
2025-09-04 08:00
Regulatory News Service
Saniona väljer SAN2668 som först-i-klassen klinisk kandidat för pediatrisk epil…
Swedish 220.1 KB
2025-09-04 08:00
Regulatory News Service
Saniona selects SAN2668 as first-in-class clinical candidate for paediatric epi…
English 218.7 KB
2025-08-28 08:00
Interim Report
Swedish 1.2 MB
2025-08-28 08:00
Interim Report
English 1.1 MB
2025-08-20 13:30
M&A Activity
Saniona ingår exklusivt licensavtal med Jazz Pharmaceuticals för att utveckla o…
Swedish 232.7 KB
2025-08-20 13:30
M&A Activity
Saniona Enters Exclusive Licensing Agreement with Jazz Pharmaceuticals to Devel…
English 233.7 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Saniona AB
Swedish 151.7 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Change in number of shares and votes in Saniona AB
English 150.7 KB
2025-06-26 17:30
Share Issue/Capital Change
Fenja Capital II A/S requests conversion of the remaining outstanding convertib…
English 146.1 KB
2025-06-26 17:30
Share Issue/Capital Change
Fenja Capital II A/S påkallar konvertering av resterande utestående konvertible…
Swedish 146.6 KB
2025-05-28 17:05
Post-Annual General Meeting Information
Kommuniké från årsstämma den 28 maj 2025 i Saniona AB
Swedish 216.1 KB
2025-05-28 17:05
Post-Annual General Meeting Information
Bulletin from the Saniona AB annual shareholders’ meeting on May 28, 2025
English 216.0 KB
2025-05-28 08:00
Earnings Release
Swedish 1.2 MB

Automate Your Workflow. Get a real-time feed of all Saniona filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Saniona

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Saniona via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-01 Thomas Feldthus Other Other 220,000 1,073,600.00 SEK
2025-04-01 Pierandrea Muglia Other Other 53,333 260,265.04 SEK
2025-04-01 Thomas Feldthus Other Other 30,000 146,400.00 SEK
2024-10-02 John Haurum Other Buy 67,100 60,363.16 SEK
2024-10-02 John Haurum Other Buy 12,361 51,415.58 SEK
2024-01-29 Pierandrea Muglia Other Other 53,333 219,731.96 SEK
2022-07-05 Karl Johan Bertil Sundberg Other Buy 40,000 142,128.00 SEK
2022-07-05 Thomas Feldthus Other Buy 30,000 130,590.00 SEK
2022-07-05 Thomas Feldthus Other Buy 30,000 129,600.00 SEK
2022-07-05 Thomas Feldthus Other Buy 5,221 22,685.24 SEK

Peer Companies

Advancing high-grade copper and precious metal projects from discovery to production.
Canada
COR
Cantargia Logo
Develops antibody treatments targeting IL1RAP for cancer and autoimmune/inflammatory diseases.
Sweden
CANTA
Captor Therapeutics S.A. Logo
Developing TPD therapeutics for oncology and autoimmune diseases with its Optigrade™ platform.
Poland
CTX
Cardiff Oncology, Inc. Logo
Clinical-stage biotech developing a PLK1 inhibitor to treat resistant cancers.
United States of America
CRDF
Cardio Diagnostics Holdings, Inc. Logo
AI-powered epigenetic and genetic tests for early detection of heart disease risk.
United States of America
CDIO
Cardiol Therapeutics Inc. Logo
Develops oral cannabidiol therapies for inflammatory and fibrotic heart diseases.
United States of America
CRDL
CareDx, Inc. Logo
Precision diagnostics and surveillance solutions for the organ transplant journey.
United States of America
CDNA
Offers one-stop BPO, CRM, and staffing for admin, manufacturing, and logistics.
Japan
6070
Caris Life Sciences, Inc. Logo
Pioneering precision cancer care via AI-powered molecular profiling and diagnostics.
United States of America
CAI
Carna Biosciences, Inc. Logo
Develops kinase inhibitor drugs for oncology/autoimmune diseases & offers discovery support services.
Japan
4572

Talk to a Data Expert

Have a question? We'll get back to you promptly.